1. |
Iapadre G, Balagura G, Zagaroli L, et al. Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents. Pediatric Drugs, 2018, 20(5): 429-453.
|
2. |
Aaberg KM, Gunnes N, Bakken IJ, et al. Incidence and prevalence of childhood epilepsy: a nationwide cohort Study. Pediatrics (Evanston), 2017, 139(5): E20163908.
|
3. |
Beghi E. The epidemiology of epilepsy. Neuroepidemiology, 2020, 54(2): 185-191.
|
4. |
中国抗癫痫协会. 临床诊断指南·癫痫病分册(2015修订版), 2015: 134.
|
5. |
Maiti R, Mishra BR, Sanyal S, et al. Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: a randomized controlled trial. Epilepsy Research, 2017, 138: 5-10.
|
6. |
Preuss RGWT. Oxcarbazepine. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2022.
|
7. |
Arya R, Glauser TA. Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. CNS Drugs, 2013, 27(4): 273-286.
|
8. |
Chen C, Zhou Y, Cui Y, et al. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. Journal of Clinical Pharmacy and Therapeutics, 2019, 44(2): 300-311.
|
9. |
Beydoun A, Dupont S, Zhou D, et al. Current role of carbamazepine and oxcarbazepine in the management of epilepsy. Seizure, 2020, 83: 251-263.
|
10. |
Chen YT, Wang CY, Yin YW, et al. Population pharmacokinetics of oxcarbazepine: a systematic review. Expert Rev Clin Pharmacol, 2021, 14(7): 853-864.
|
11. |
Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Research, 2015, 110: 189-205.
|
12. |
Wilson SM, Khanna R. Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide. Mol Neurobiol, 2015, 51(2): 599-609.
|
13. |
Arzimanoglou A, Cruz ON, Nordli D, et al. A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation. Pediatric Drugs, 2018, 20(3): 249-264.
|
14. |
贺欢, 肖农. 拉考沙胺在儿童癫痫治疗中的研究进展. 中国实用儿科杂志, 2020, 35(05): 406-410.
|
15. |
Cawello W, Stockis A, Andreas J, et al. Advances in epilepsy treatment: lacosamide pharmacokinetic profile. Annals of the New York Academy of Sciences, 2014, 1329(1): 18-32.
|
16. |
Wang Y, Chen Y, Zhang Y, et al. Oxcarbazepine oral suspension in pediatric patients with partial seizures and/or generalized tonic-clonic seizures: a multi-center, single arm, observational study in China. World Journal of Pediatrics, 2017, 13(6): 551-559.
|
17. |
Zhu H, Deng X, Feng L, et al. Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: a multicenter, open‐label, randomized study. CNS Neuroscience & Therapeutics, 2022, 28(7): 1072-1080.
|
18. |
Mehrotra S, Bhattaram A, Krudys K, et al. Extrapolation of efficacy from adults to pediatric patients of drugs for treatment of partial onset seizures: a regulatory perspective. Clinical Pharmacology & Therapeutics, 2022, 112(4): 853-863.
|
19. |
Li R, Zhou Q, Ou S, et al. Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world. Epilepsy Research, 2020, 166: 106408.
|
20. |
Zhao B, Liao S, Zhong X, et al. Effectiveness and safety of oxcarbazepine vs. levetiracetam as monotherapy for infantile focal epilepsy:a longitudinal cohort study. Frontiers in Neurology, 2022, 13: 909191.
|
21. |
Geng H, Wang C. Efficacy and safety of oxcarbazepine in the treatment of children with epilepsy: a meta-analysis of randomized controlled trials. Epilepsy Research, 2017, 13: 685-695.
|
22. |
赵斯钰, 岩吴. 拉莫三嗪与奥卡西平初始单药治疗新诊断BEC T药物保留率及疗效研究. 中国妇幼健康研究, 2021, 32(12): 1782-1787.
|
23. |
Suo G, Zheng Y, Wu Y, et al. Effects of levetiracetam and oxcarbazepine monotherapy on intellectual and cognitive development in children with benign epilepsy with centrotemporal spikes. Acta Neurologica Belgica, 2021, 121(5): 1265-1273.
|
24. |
Toohey CV, Middleman AB. Hypogammaglobulinemia associated with oxcarbazepine use in a teen. Pediatric Neurology, 2022, 134: 67-70.
|
25. |
iauškaitė J, Gelžinienė G, Jurkevičienė G. Oxcarbazepine and hyponatremia. Medicina, 2022, 58(5): 559.
|
26. |
Ley APRR. Efectos a largo plazo de las dibenzacepinas sobre los parámetros metabólicos: comparación retrospectiva de carbamacepina, oxcarbacepina y acetato de eslicarbacepina en el mundo real. Rev Neurol-FRANCE, 2020, 71(2): 54-60.
|
27. |
Han, Min Jeong et al. Effect of oxcarbazepine on language function in patients with newly diagnosed pediatric epilepsy. Journal of Clinical Neurology, 2023, 19(1): 76.
|
28. |
Eun S, Kim HD, Chung HJ, et al. A multicenter trial of oxcarbazepine oral suspension monotherapy in children newly diagnosed with partial seizures: a clinical and cognitive evaluation. Seizure, 2012, 21(9): 679-684.
|
29. |
Hamed SA. The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert Review of Clinical Pharmacology, 2015, 8(6): 741-750.
|
30. |
Park H, Heo J, Kim MJ, et al. The longitudinal effect of oxcarbazepine on thyroid function in children and adolescents with epilepsy. Epilepsia, 2022, 63(12): 3148-3155.
|
31. |
Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology, 2019, 93(12): e1212-e1226.
|
32. |
Romão TT, Angelim AIM, Prado HJPD, et al. Use of lacosamide in children: experience of a tertiary medical care center in Brazil. Arquivos de Neuro-Psiquiatria, 2022, 80(11): 1090-1096.
|
33. |
Hmaimess G, Sabbagh S, Dirani M, et al. Efficacy and tolerability of treatment with lacosamide in children: postmarketing experience from the middle east. Seizure, 2020, 79: 75-79.
|
34. |
Zhao T, Li H, Ma L, et al. Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China. Epilepsy & Behavior, 2021, 117: 107814.
|
35. |
Gulati P, Cannell P, Ghia T, et al. Lacosamide as adjunctive therapy in treatment-resistant epilepsy in childhood. Journal of Paediatrics and Child Health, 2015, 51(8): 794-797.
|
36. |
Yang C, Yang Y, Peng Y, et al. Efficacy and safety of lacosamide in pediatric patients with epilepsy: a systematic review and meta-analysis. Epilepsy & Behavior, 2022, 134: 108781.
|
37. |
Okanishi T, Fujii Y, Sakuma S, et al. Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes. Brain and Development, 2022, 44(6): 380-385.
|
38. |
冯隽, 汤继宏, 张兵兵, 等. 拉考沙胺单药治疗儿童良性癫痫伴中央颞区棘波的临床分析. 癫痫杂志, 2021, 7(6): 477-480.
|
39. |
Ferreira J A, Le Pichon J, Abdelmoity A T, et al. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – an open-label trial. Seizure, 2019, 71: 166-173.
|
40. |
吉明明, 温冬香, 廖瑶琪, 等. 拉考沙胺治疗局灶性癫痫发作患儿的效果观察. 中国医学创新, 2022, 19(20): 30-34.
|
41. |
Driessen JT, Wammes Van DHEA, Verschuure P, et al. Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy. Epilepsy & Behavior Reports, 2023, 21: 100574.
|
42. |
Ishikawa N, Eguchi Y, Izumo H, et al. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: a cohort study. Epilepsy & Behavior, 2022, 129: 108614.
|
43. |
Yorns WR, Khurana DS, Carvalho KS, et al. Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy. Journal of Child Neurology, 2014, 29(1): 23-27.
|
44. |
Rüegger, Andrea D et al. Lacosamide in children with drug-resistant epilepsy. Journal of Paediatrics and Child Health, 2019, 55(2): 194-198.
|
45. |
Biton V, Gil-Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy & Behavior, 2015, 52: 119-127.
|
46. |
Li K, Huang L, Chang Y, et al. The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy. Epilepsy & Behavior, 2020, 113: 107580.
|
47. |
Bosak M, Wężyk K, Słowik A. Lacosamide and myoclonic seizures: what is the risk of aggravation? Neurologia I Neurochirurgia Polska, 2021, 55(1): 107-109.
|
48. |
Gul A, Mehreen S. Effectiveness of Lacosamide on every day cognitive deficits, psychiatric symptoms and resilience in patients with epilepsy. Journal of the Pakistan Medical Association, 2020, 70(9): 1611-1615.
|
49. |
Meschede C, Witt J, Rademacher M, et al. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure, 2018, 58: 141-146.
|
50. |
Pasha I, Kamate M, Suresh DK. Safety of lacosamide in children with refractory partial epilepsy. Saudi Pharmaceutical Journal, 2015, 23(5): 556-561.
|
51. |
Panda PK, Sharawat IK. Impact of carbamazepine and lacosamide on serum lipid levels. Epilepsia, 2021, 62(4): 1034-1035.
|
52. |
Matsudaira T, Terada T, Araki Y, et al. HyperCKemia associated with lacosamide therapy in an elderly patient with focal onset epilepsy. Seizure, 2018, 63: 14-16.
|
53. |
Gupta SS, Patti R, Lindsay D, et al. Lacosamide: associated hyponatremia. Am J Ther, 2018, 25(6): e729-e730.
|
54. |
Simko J, Fekete S, Malakova J, et al. The effect of lacosamide on bone tissue in orchidectomised male albino Wistar rats. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015, 159(3): 394-399.
|
55. |
Yadav R, Schrem E, Yadav V, et al. Lacosamide-related arrhythmias: a systematic analysis and review of the literature. Cureus. 2021;13(12): e20736.
|
56. |
Tateishi Y, Ishikawa N, Kobayashi Y, et al. Effect of Lacosamide therapy on blood cells and IgA levels in children and adolescents with epilepsy in a clinical setting. Epilepsy Research, 2022, 187: 107030.
|
57. |
Buraniqi E, Dabaja H, Wirrell E C. Impact of antiseizure medications on appetite and weight in children. Paediatric drugs, 2022, 24(4): 335-363.
|
58. |
Madani N, O Malley JA, Porter B E, et al. Lacosamide-induced dyskinesia in children with intractable epilepsy. Journal of child neurology, 2020, 35(10): 662-666.
|
59. |
Zhao X, Liu Y, Xu Z. A paediatric case of lacosamide‐induced panniculitis. Australasian Journal of Dermatology, 2022, 63(1): e107-e109.
|